Study Evaluating Genotypes Using Lucentis

Stopped early

Conditions studied: Age-Related Maculopathy

In brief

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

Key facts

Study ID

NCT00474695

Run by

University of Utah

People needed

65

Starts

2007-05-01

Expected to finish

2009-12-01

Last updated by the study team

2015-02-11

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Treatment naive AMD patients;
• At least 50 years of age;
• Visual acuity between 20/40 and 20/320

You may not qualify if…

• Pregnancy;
• Prior enrollment in a ranibizumab clinical trial;
• Previous therapy in either eye for AMD;
• Concurrent eye disease that could compromise visual acuity

Where it is running

• California Retina Consultants — Santa Barbara, California, United States
• Porter Adventist Hospital — Denver, Colorado, United States
• University of Utah, Moran Eye Center — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.